Document Detail

Cytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomics.
MedLine Citation:
PMID:  19623099     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: 5'-Nucleotidases play a critical role in nucleotide pool balance and in the metabolism of nucleoside analogs such as gemcitabine and cytosine arabinoside (AraC). We previously performed an expression array association study with gemcitabine and AraC cytotoxicity using 197 human lymphoblastoid cell lines. One gene that was significantly associated with gemcitabine cytotoxicity was a nucleotidase family member, NT5C3. Very little is known with regard to the pharmacogenomics of this family of enzymes.
METHODS: We set out to identify common genetic variation in NT5C3 by resequencing the gene and to determine the effect of that variation on NT5C3 protein function and potential effect on response to cytidine analogs. We identified 61 NT5C3 polymorphisms, 48 of which were novel, by resequencing 240 ethnically defined DNA samples. Functional studies were performed with one nonsynonymous (G847C, Asp283His) and four synonymous cSNPs (T9C, C276T, T306C, and G759A),as well as three combined variants (T276/His283, T276/C306, T276/C9).
RESULTS: The His283 and T276/His283 constructs showed decreased levels of enzyme activity and protein. Substrate kinetic analysis showed no significant differences in Km values between wild type and His283 when cytidine monophosphate, AraCMP, and GemMP were used as substrates. An association study between single nucleotide polymorphisms (SNPs) and NT5C3 expression in the 240 cell lines from which DNA was extracted to resequence NT5C3 identified four SNPs that were significantly associated with NT5C3 expression. Electrophoretic mobility shift assays showed that two of those SNPs, I4(-114) and I6(9), altered DNA-protein binding patterns. These findings suggest that genetic variation in NT5C3 might affect protein function and potentially influence drug response.
Pinar Aksoy; Min Jia Zhu; Krishna R Kalari; Irene Moon; Linda L Pelleymounter; Bruce W Eckloff; Eric D Wieben; Vivien C Yee; Richard M Weinshilboum; Liewei Wang
Related Documents :
20021689 - Association of a functional microsatellite within intron 1 of the bmp5 gene with suscep...
15094789 - A major snp haplotype of the arginine vasopressin 1b receptor protects against recurren...
15363219 - Analysis of polymorphisms in the promoter region of interleukin-1beta by restriction fr...
20186139 - Interleukin-6 receptor gene polymorphism modulates interleukin-6 levels and the metabol...
12820449 - Evidence-based prevention (ebp): approach to lung cancer prevention based on cytochrome...
20418889 - Meta-analysis and imputation refines the association of 15q25 with smoking quantity.
17236139 - Mutations in cul4b, which encodes a ubiquitin e3 ligase subunit, cause an x-linked ment...
11921059 - Late-onset frontotemporal dementia with a novel exon 1 (arg5his) tau gene mutation.
20120899 - Association of single nucleotide polymorphisms in adiponectin and its receptor genes wi...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pharmacogenetics and genomics     Volume:  19     ISSN:  1744-6872     ISO Abbreviation:  Pharmacogenet. Genomics     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-07-30     Completed Date:  2009-09-11     Revised Date:  2014-09-24    
Medline Journal Info:
Nlm Unique ID:  101231005     Medline TA:  Pharmacogenet Genomics     Country:  United States    
Other Details:
Languages:  eng     Pagination:  567-76     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
5'-Nucleotidase / genetics*
Antimetabolites, Antineoplastic / pharmacology
COS Cells
Cell Line, Tumor
Cercopithecus aethiops
Cytarabine / pharmacology
DNA / chemistry
Deoxycytidine / analogs & derivatives,  pharmacology
Genetic Variation*
Glycoproteins / genetics*
Models, Genetic
Pharmacogenetics / methods
Grant Support
K22 CA130828/CA/NCI NIH HHS; K22 CA130828/CA/NCI NIH HHS; K22 CA130828-01A1/CA/NCI NIH HHS; K22 CA130828-02/CA/NCI NIH HHS; R01 CA132780/CA/NCI NIH HHS; R01 CA132780/CA/NCI NIH HHS; R01 CA132780-01/CA/NCI NIH HHS; R01 CA132780-02/CA/NCI NIH HHS; R01 CA138461/CA/NCI NIH HHS; R01 CA138461/CA/NCI NIH HHS; R01 CA138461-01/CA/NCI NIH HHS; R01 GM028157/GM/NIGMS NIH HHS; R01 GM028157-28/GM/NIGMS NIH HHS; R01 GM028157-29/GM/NIGMS NIH HHS; R01 GM035720/GM/NIGMS NIH HHS; R01 GM035720-20/GM/NIGMS NIH HHS; R01 GM035720-21/GM/NIGMS NIH HHS; R01 GM28157/GM/NIGMS NIH HHS; R01 GM35720/GM/NIGMS NIH HHS; U01 GM061388/GM/NIGMS NIH HHS; U01 GM061388-09/GM/NIGMS NIH HHS; U01 GM61388/GM/NIGMS NIH HHS
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 0/Glycoproteins; 04079A1RDZ/Cytarabine; 0W860991D6/Deoxycytidine; 9007-49-2/DNA; B76N6SBZ8R/gemcitabine; EC'-Nucleotidase; EC protein, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Piezoelectric round window osteoplasty for Vibrant Soundbridge implant.
Next Document:  Irritable bowel syndrome subtypes defined by Rome II and Rome III criteria are similar.